B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains a buyer on share weakness following the Q4 report. The analyst left the earnings call “particularly encouraged” by the oral VK2735 delivering on “injectables’-like” weight loss data, which Riley believes would be unprecedented in the space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics price target lowered to $70 from $120 at Maxim
- Viking Therapeutics initiated with a Neutral at Citi
- Viking Therapeutics Reports Strong Trials and Financial Health
- Viking Therapeutics price target raised to $125 from $122 at Raymond James
- Viking Therapeutics Reports Positive 2024 Financials and Clinical Progress
Questions or Comments about the article? Write to editor@tipranks.com